Biotechnology · global
Oncolytics Advances RAS-Mutant Colorectal Cancer Trial, With FDA Meeting as Next Hurdle
Whether pelareorep can bring immunotherapy into hard-to-treat MSS metastatic colorectal cancer will still have to be shown by a randomized trial; the focus of this progress is not a promise of efficacy, but that the trial is moving closer to a registrational path.
For many patients with metastatic colorectal cancer, the tumor’s molecular characteristics often determine from the outset how narrow the treatment options are. The combination of RAS mutation and microsatellite-stable (MSS) disease typically does not readily derive clear benefit from existing immune checkpoint inhibitors, so any strategy that attempts to reopen an immune response must undergo more rigorous clinical validation.
On July 13, Oncolytics Biotech said its REO 033 randomized controlled trial is evaluating pelareorep in combination with FOLFIRI and bevacizumab for second-line treatment of RAS-mutant, MSS metastatic colorectal cancer. The company said about half of the planned clinical trial sites could be activated by the end of July 2026, with the remaining sites expected to be in place by the end of August; participating sites have already pre-identified more than 20 potential subjects.
The regulatory significance of this trial is that Oncolytics is preparing to hold a Type D meeting with the U.S. FDA in the first half of August 2026 to discuss whether to add a registrationally designed Part B under the existing REO 033 structure. According to the company, Part B would retain the core design of REO 033 while expanding enrollment and incorporating blinded independent central review, with the goal of giving the same study the potential to support discussions of accelerated approval and full approval.
Pelareorep is an investigational intravenously administered double-stranded RNA immunotherapy. Oncolytics argues that it may shift a tumor microenvironment with a relatively weak immune response toward a more active state by activating innate and adaptive immune responses; however, this kind of mechanistic narrative must be considered separately from clinical endpoints. The value of REO 033 is precisely that it puts signals from earlier-stage studies to the test in a randomized design with a contemporary control arm.
The company noted that REO 033 builds on efficacy signals seen in the earlier REO 022 study, including improvements in progression-free survival, overall survival, duration of response, and objective response rate compared with historical standard-of-care benchmarks; pelareorep has also received FDA Fast Track designation in this indication. However, historical controls and randomized controls carry different evidentiary weight, especially in late-stage cancer trials, where patient composition, subsequent therapy, and assessment methods can all change how results are interpreted.
The next timeline remains conditional. Oncolytics expects to report an initial tumor response update from patients enrolled in Part A by the end of 2026; if FDA feedback is supportive, the company hopes to begin Part B enrollment in the first quarter of 2027. In other words, this announcement shows that trial execution and regulatory communication are moving forward, but it is not yet equivalent to proving that pelareorep can change the standard of care for RAS-mutant MSS metastatic colorectal cancer. The real question remains whether the randomized data can hold up simultaneously on efficacy, safety, and reviewable quality.